November 8, 2014
Record Number: 4456Author: Ekelund, M., Mallbris, L., Qvitzau, S. and Stenberg, B.
Title: A higher score on the dermatology life quality index, being on systemic treatment and having a diagnosis of psoriatic arthritis is associated with increased costs in patients with plaque psoriasis
Journal: Acta Derm Venereol
Short Title: A higher score on the dermatology life quality index, being on systemic treatment and having a diagnosis of psoriatic arthritis is associated with increased costs in patients with plaque psoriasis
Alternate Journal: Acta dermato-venereologica
ISSN: 1651-2057 (Electronic)
Accession Number: 23603935
Arthritis, Psoriatic/*diagnosis/drug therapy/*economics/psychology
Cost of Illness
*Health Care Costs
Predictive Value of Tests
*Quality of Life
Severity of Illness Index
Abstract: The aim of this study was to examine the relationship between measures of disease severity and costs from a societal perspective in patients with plaque psoriasis. Dermatologists in Sweden recruited 443 consecutive patients who had had no biological treatment during the past 12 months. Following a Psoriasis Area and Severity Index (PASI) assessment, subjects completed self-assessments on health status/quality of life and a healthcare resource utilization/work status questionnaire. The costs of healthcare resources and sick-leave due to plaque psoriasis were estimated and related to the subject’s health status. A patient’s Dermatology Life Quality Index (DLQI) and being on systemic therapy, or having diagnosis of psoriatic arthritis, appeared to be more strongly associated with direct and indirect costs than did their PASI. The cost of biological therapy should be considered from the perspective of the already high costs of patients with high DLQI undergoing traditional systemic treatment.